Biology of systems in characterising the response to biological drugs in the treatment of inflammatory bowel disease (Q3158316): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: translated_label) |
(Removed claim: summary (P836): Inflammatory bowel disease is a significant public health problem due to its increasing incidence, appearance in the first decades of life, and chronic and sometimes invalidating condition. The key to the treatment of moderate to severe disease is anti-TNF monoclonal antibodies. However, one third of patients do not respond to treatment, and of those who do so at least another third will lose their response in the first year of treatment. It i...) |
||||||||||||||
| Property / summary | |||||||||||||||
| Property / summary: Inflammatory bowel disease is a significant public health problem due to its increasing incidence, appearance in the first decades of life, and chronic and sometimes invalidating condition. The key to the treatment of moderate to severe disease is anti-TNF monoclonal antibodies. However, one third of patients do not respond to treatment, and of those who do so at least another third will lose their response in the first year of treatment. It is speculated that the reasons are of a different nature: pharmacokinetics, immunogenity and others of unknown type. In these circumstances, you can sometimes optimise the dose, or add immunomodulators, or in case of therapeutic failure, change the molecule. Drugs against other targets have been developed but do not seem more effective than anti-TNFs. There is, therefore, an orphaned situation of effective therapy. It is necessary to know the causes of the lack of effectiveness and to develop a predictive tool that allows the best therapeutic strategy. Our objective is to develop a predictive mathematical model of efficacy to anti-TNF treatment as a decision-making tool to apply in clinical practice in moderate or severe IBD, through the integration of different omics-transcriptomics, pharmacogenetics, metabolomics and pharmacokinetic behavior to characterise new functional roles involved in drug response. (English) / rank | |||||||||||||||
| Property / summary: Inflammatory bowel disease is a significant public health problem due to its increasing incidence, appearance in the first decades of life, and chronic and sometimes invalidating condition. The key to the treatment of moderate to severe disease is anti-TNF monoclonal antibodies. However, one third of patients do not respond to treatment, and of those who do so at least another third will lose their response in the first year of treatment. It is speculated that the reasons are of a different nature: pharmacokinetics, immunogenity and others of unknown type. In these circumstances, you can sometimes optimise the dose, or add immunomodulators, or in case of therapeutic failure, change the molecule. Drugs against other targets have been developed but do not seem more effective than anti-TNFs. There is, therefore, an orphaned situation of effective therapy. It is necessary to know the causes of the lack of effectiveness and to develop a predictive tool that allows the best therapeutic strategy. Our objective is to develop a predictive mathematical model of efficacy to anti-TNF treatment as a decision-making tool to apply in clinical practice in moderate or severe IBD, through the integration of different omics-transcriptomics, pharmacogenetics, metabolomics and pharmacokinetic behavior to characterise new functional roles involved in drug response. (English) / qualifier | |||||||||||||||
| |||||||||||||||
Revision as of 16:28, 12 October 2021
Project Q3158316 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Biology of systems in characterising the response to biological drugs in the treatment of inflammatory bowel disease |
Project Q3158316 in Spain |
Statements
80,000.0 Euro
0 references
100,000.0 Euro
0 references
80.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
0 references
42°52'49.51"N, 8°32'45.10"W
0 references
15078
0 references
La enfermedad inflamatoria intestinal supone un notable problema de salud pública por su creciente incidencia, aparición en las primeras décadas de la vida, y condición crónica y a veces invalidante. La clave del tratamiento de la enfermedad moderada a grave son los anticuerpos monoclonales anti-TNF. Sin embargo, un tercio de los pacientes no responden al tratamiento, y de aquellos que lo hacen al menos otro tercio perderá la respuesta en el primer año de tratamiento. Se especula que las razones son de naturaleza diversa: farmacocinética, inmunogenidad y otras de tipo desconocido. En estas circunstancias, se puede optimizar en ocasiones la dosis, o añadir inmunomoduladores, o en caso de fracaso terapéutico, cambiar de molécula. Se han desarrollado fármacos contra otras dianas pero no parecen más efectivos que los anti-TNF. Queda, por tanto, una situación huérfana de terapia efectiva. Es preciso conocer las causas de la falta de eficacia y desarrollar una herramienta predictiva que permita la mejor estrategia terapéutica. Nuestro objetivo es desarrollar un modelo matemático predictivo de eficacia al tratamiento anti-TNF como herramienta de decisión para aplicar en la práctica clínica en la EII moderada o grave, a través de la integración de diferentes ómicas-transcriptómica, farmacogenética, metabolómica y con el comportamiento farmacocinético para caracterizar nuevos papeles funcionales implicados en la respuesta a los fármacos. (Spanish)
0 references
Santiago de Compostela
0 references
Identifiers
PI17_00190
0 references